Spinouts
Explore our portfolio below. We typically launch 3 new companies every year, with plans to step this up, so follow us on LinkedIn to stay up to date with our work.
Queen Mary spinout companies raised £5m in investment in 2022/23, and have raised over £100m since 2018/19. If you’re an investor, it’s best to contact the company directly to learn what form of investment they’re looking for.
We work with around 150 researchers each year to assess the viability of their inventions. We’ve worked with 650 individual researchers since 2018/19. If you’re a researcher at Queen Mary, get in touch to discuss how we can help you develop your idea into a business.
Our spinouts are special because they are the fruits of significant scientific discoveries. 92% of our research is world leading or internationally excellent (REF 2021) and we’re ranked 14th in the world for the quality of our research (THE World University Ranking 2024).
New Companies
Nilocas
Nilocas Ltd is developing a medical device to revolutionise the detection of Coronary Artery Disease.
Enterika
A nutrient-based appetite-suppressing pill to treat obesity. Enterika harnesses the power of your own body to naturally reduce appetite.
Tabletop R&D
AI-powered playtesting for designing better board games faster.
SequenceServer
Intuitive comparison and visualisation of DNA and protein sequences.
AeroSolar
Manufacturing a new kind of solar cell made from perovskite.
Pryfiber
An AI algorithm for real-time image calibration during surgical or imaging procedures.
Nemisindo
Generating unique sound effects in real time using AI.
RoEx
Using AI to transform how musicians of all skill levels produce and record new music.
Growing Companies
Ultima Forma
Extending the limits of product performance with advanced forming technology.
VacV Biotherapeutics
An immunotherapy company developing viral-based therapies for cancer.
Kinomica
A diagnostic platform to help clinicians prescribe the right drug, for the right patient, at the right time.
BioMin
BioMin glass is a dental additive for complete oral care and protection.
Warblr
An iPhone and Android app that automatically recognises British birds by their song.
Keratify
A more effective way to maintain skin in culture.
DAACI AI
DAACI’s generative tech encodes composers’ musical ideas, allowing their AI to dynamically compose in real time without relying on pre-recorded samples.
Established Companies
Dragonfly AI
A biologically inspired algorithm to test creative content by predicting human attention.
Arbitrator Intelligence
Transparency, accountability, and diversity in arbitrator selection.
Bela
The finest tools for ambitious creators who are working with sensors and sound.
LANDR
AI-powered music mastering, distribution, plugins, collaboration, promotion and sample packs.
Chatterbox Labs
Addressing the unintended consequences of AI.
hVIVO
The world leader in human challenge studies to test infectious and respiratory products.
The Government’s spinout review
We are pleased to be incorporating the good practice recommendations from the Government spinout review in its policy and practices. In particular we welcome the work done by TenU and major investors in developing the USIT guides as a landing zone and foundation for good practices and we will be using them in our commercialisation activities.
At Queen Mary Innovation we work on behalf of the University to maximise the impact of Queen Mary Research using commercial tools and implements the University Intellectual Property policy. The primary goal is to ensure economic and social impact, and any returns are shared with innovative creators and venture founders, reinvested in new ventures, or in the University’s charitable mission.
Following the Government review the University is currently reviewing its Intellectual Property Policy, which covers more than just the creation of spinouts and requires wider consultation. Nevertheless, recognising the importance of increasing the speed and scale of spinouts as quickly as possible, the University has approved a new Commercialisation and Benefit Sharing Policy which will operate from the 5th July 2024 and will be incorporated into the full Intellectual Property policy once the review is complete.
We will immediately implement the policy and we’ll continue to review its procedures to identify areas where decision making can sensibly be streamlined to ensure speedier conclusion of discussions with investors and stakeholders.